RESUMO
OBJECTIVE: The aim was to evaluate the impact of bariatric surgery on cardiac and sudomotor autonomic C-fiber function in obese subjects with and without Type 2 diabetes mellitus (T2DM), using sudorimetry and heart rate variability (HRV) analysis. METHOD: Patients were evaluated at baseline, 4, 12 and 24 weeks after vertical sleeve gastrectomy or Roux-en-Y gastric bypass. All subjects were assessed using SudoscanTM to measure electrochemical skin conductance (ESC) of hands and feet, time and frequency domain analysis of HRV, Neurologic Impairment Scores of lower legs (NIS-LL), quantitative sensory tests (QST) and sural nerve conduction studies. RESULTS: Seventy subjects completed up to 24-weeks of follow-up (24 non-T2DM, 29 pre-DM and 17 T2DM). ESC of feet improved significantly towards normal in T2DM subjects (Baseline = 56.71±3.98 vs 12-weeks = 62.69±3.71 vs 24-weeks = 70.13±2.88, p<0.005). HRV improved significantly in T2DM subjects (Baseline sdNN (sample difference of the beat to beat (NN) variability) = 32.53±4.28 vs 12-weeks = 44.94±4.18 vs 24-weeks = 49.71±5.19, p<0,001 and baseline rmsSD (root mean square of the difference of successive R-R intervals) = 23.88±4.67 vs 12-weeks = 38.06±5.39 vs 24-weeks = 43.0±6.25, p<0.0005). Basal heart rate (HR) improved significantly in all groups, as did weight, body mass index (BMI), percent body fat, waist circumference and high-density lipoprotein (HDL). Glycated hemoglobin (HbA1C), insulin and HOMA2-IR (homeostatic model assessment) levels improved significantly in pre-DM and T2DM subjects. On multiple linear regression analysis, feet ESC improvement was independently associated with A1C, insulin and HOMA2-IR levels at baseline, and improvement in A1C at 24 weeks, after adjusting for age, gender and ethnicity. Sudomotor function improvement was not associated with baseline weight, BMI, % body fat or lipid levels. Improvement in basal HR was also independently associated with A1C, insulin and HOMA2-IR levels at baseline. CONCLUSION: This study shows that bariatric surgery can restore both cardiac and sudomotor autonomic C-fiber dysfunction in subjects with diabetes, potentially impacting morbidity and mortality.
Assuntos
Sistema Nervoso Autônomo/fisiopatologia , Cirurgia Bariátrica , Diabetes Mellitus Tipo 2/complicações , Coração/fisiopatologia , Fibras Nervosas/fisiologia , Obesidade/cirurgia , Glândulas Sudoríparas/fisiopatologia , Adulto , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Obesidade/complicações , Obesidade/fisiopatologia , Recuperação de Função Fisiológica , Resultado do TratamentoRESUMO
CONTEXT: Visceral adipose tissue (VAT) is a key contributor to chronic inflammation in obesity. The 12/15-lipoxygenase pathway (ALOX) is present in adipose tissue (AT) and leads to inflammatory cascades that are causal for the onset of insulin resistance in rodent models of obesity. OBJECTIVE: The pathophysiology of the ALOX 12/15 pathway in human AT is unknown. We characterized the ALOX pathway in different AT depots in obese humans with or without type 2 diabetes (T2D). DESIGN: This study includes a cross-sectional cohort of 46 morbidly obese (body mass index >39 kg/m(2)) nondiabetic (n = 25) and T2D (n = 21) subjects. SETTING: This study was conducted at Eastern Virginia Medical School (Norfolk, Virginia) in collaboration with Sentara Metabolic and Weight Loss Surgery Center (Sentara Medical Group, Norfolk, Virginia). PATIENTS: Twenty-five obese (body mass index 44.8 ± 4.4 kg/m(2)) nondiabetic (hemoglobin A1c 5.83% ± 0.27%) and 21 obese (43.4 ± 4.1 kg/m(2)) and T2D (hemoglobin A1c 7.66% ± 1.22%) subjects were included in the study. The subjects were age matched and both groups had a bias toward female gender. MAIN OUTCOMES AND MEASURES: Expression of ALOX isoforms along with fatty acid substrates and downstream lipid metabolites were measured. Correlations with depot-specific inflammatory markers were also established. RESULTS: ALOX 12 expression and its metabolite 12(S)-hydroxyeicosatetraenoic acid were significantly increased in the VAT of T2D subjects. ALOX 15A was exclusively expressed in VAT in both groups. ALOX 12 expression positively correlated with expression of inflammatory genes IL-6, IL-12a, CXCL10, and lipocalin-2. CONCLUSIONS: ALOX 12 may have a critical role in regulation of inflammation in VAT in obesity and T2D. Selective ALOX 12 inhibitors may constitute a new approach to limit AT inflammation in human obesity.
Assuntos
Araquidonato 12-Lipoxigenase/metabolismo , Araquidonato 15-Lipoxigenase/metabolismo , Diabetes Mellitus Tipo 2/enzimologia , Gordura Intra-Abdominal/enzimologia , Obesidade Mórbida/enzimologia , Adolescente , Adulto , Idoso , Araquidonato 12-Lipoxigenase/genética , Araquidonato 15-Lipoxigenase/genética , Biomarcadores/metabolismo , Estudos Transversais , Diabetes Mellitus Tipo 2/genética , Diabetes Mellitus Tipo 2/imunologia , Ácidos Graxos/metabolismo , Feminino , Regulação Enzimológica da Expressão Gênica/imunologia , Hemoglobinas Glicadas/metabolismo , Humanos , Inflamação/enzimologia , Inflamação/genética , Inflamação/imunologia , Gordura Intra-Abdominal/imunologia , Metabolismo dos Lipídeos/genética , Metabolismo dos Lipídeos/imunologia , Masculino , Pessoa de Meia-Idade , Obesidade Mórbida/genética , Obesidade Mórbida/imunologia , Adulto JovemRESUMO
Assessing the percent BSA involved in a burn is essential in patient management. The "Rule of Nines" is one traditional method of estimating BSA. This rule assumes that adults have the same distribution of BSA percentages, regardless of body shape and weight. With increasing obesity, the percentages assigned to each body part may deviate from this formula. This project investigates the applicability of the "Rule of Nines" to the obese patient population. Two hundred obese adults underwent three-dimensional whole body scanning using a commercially available white light scanning device. Software was programmed to determine the surface area of the arms, torso, and legs. A measurement of TBSA and percentages associated with those body parts was derived. Additional software was used to quantify body shapes as android, gynecoid, or mixed. Height, weight, body mass index, and sex were tabulated and a statistical analysis was performed. The average surface area of the torso, arms, and legs differed among the obese and nonobese population. The surface area of the torso, arms, and legs in the obese patient was 52, 7, and 15% respectively compared with 36, 9, and 18% in the nonobese population (P = .98). Android shapes had an average torso surface area of 53% while gynecoid shapes had an average torso surface area of 48% (P = .97). A "rule of sevens" appears to be a more appropriate method for estimating BSA in the morbidly obese patient.
Assuntos
Superfície Corporal , Queimaduras/patologia , Obesidade Mórbida/complicações , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Índice de Massa Corporal , Feminino , Humanos , Processamento de Imagem Assistida por Computador , Escala de Gravidade do Ferimento , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Somatotipos , Adulto JovemRESUMO
Adipose tissue inflammation in obesity is a major factor leading to cardiovascular disease and type 2 diabetes.12/15 lipoxygenases (ALOX) play an important role in the generation of inflammatory mediators, insulin resistance and downstream immune activation in animal models of obesity. However, the expression and roles of 12/15ALOX isoforms, and their cellular sources in human subcutaneous (sc) and omental (om) fat in obesity is unknown. The objective of this study was to examine the gene expression and localization of ALOX isoforms and relevant downstream cytokines in subcutaneous (sc) and omental (om) adipose tissue in obese humans. Paired biopsies of sc and om fat were obtained during bariatric surgeries from 24 morbidly obese patients. Gene and protein expression for ALOX15a, ALOX15b and ALOX 12 were measured by real-time PCR and western blotting in adipocytes and stromal vascular fractions (SVF) from om and sc adipose tissue along with the mRNA expression of the downstream cytokines IL-12a, IL-12b, IL-6, IFNγ and the chemokine CXCL10. In a paired analysis, all ALOX isoforms, IL-6, IL-12a and CXCL10 were significantly higher in om vs. sc fat. ALOX15a mRNA and protein expression was found exclusively in om fat. All of the ALOX isoforms were expressed solely in the SVF. Further fractionation of the SVF in CD34+ and CD34- cells indicated that ALOX15a is predominantly expressed in the CD34+ fraction including vascular and progenitor cells, while ALOX15B is mostly expressed in the CD34- cells containing various leucocytes and myeloid cells. This result was confirmed by immunohistochemistry showing exclusive localization of ALOX15a in the om fat and predominantly in the vasculature and non-adipocyte cells. Our finding is identifying selective expression of ALOX15a in human om but not sc fat. This is a study showing a major inflammatory gene exclusively expressed in visceral fat in humans.
Assuntos
Tecido Adiposo/enzimologia , Araquidonato 12-Lipoxigenase/metabolismo , Araquidonato 15-Lipoxigenase/metabolismo , Obesidade/enzimologia , Adulto , Araquidonato 12-Lipoxigenase/genética , Araquidonato 15-Lipoxigenase/genética , Citocinas/metabolismo , Feminino , Humanos , Isoenzimas/genética , Isoenzimas/metabolismo , Masculino , Pessoa de Meia-IdadeRESUMO
The disease of obesity has continued to increase in the United States. Obesity is defined as a body mass index (BMI) greater than 30 kg/m(2). In 1991, the National Institute of Health Consensus Panel on Gastric Surgery for Severe Obesity defined the population who would most likely benefit from bariatric surgery. These same criteria continue to be used today to determine which patients should undergo metabolic and weight loss surgery. These recommendations include patients who have a BMI greater than 35 kg/m(2) with significant comorbid conditions such as diabetes, hypertension, or obstructive sleep apnea; and patients who have a BMI greater than 40 kg/m(2) with or without any significant comorbid conditions because they have a significant increased risk for developing these conditions.